Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Four and a half LIM domains 1
(
FHL1
) belongs to a family of LIM-only proteins that regulate gene transcription, cell proliferation, differentiation and apoptosis. However, the biological function of
FHL1
remains largely unknown. We used a yeast two-hybrid system and identified receptor interacting protein of 140kDa (RIP140) as a novel
FHL1
-binding protein. RIP140 interacted with
FHL1
both in vitro and in mammalian cells and estrogen enhanced this interaction. All domains of
FHL1
are required to interact with RIP140. Overexpression of
FHL1
enhanced RIP140 repression of estrogen signaling in breast cancer cells in a reporter assay, whereas reduction of endogenous
FHL1
with
FHL1
small interfering RNA abolished this effect. Furthermore, overexpression of the
FHL1
deletion mutant that lacks the RIP140-binding sites had no effect on RIP140 repression of estrogen signaling. Consistent with the results of the reporter assays,
FHL1
and RIP140 synergistically inhibited the transcription of the estrogen-responsive gene
pS2
. The results presented here suggested the cooperative transcriptional regulation of estrogen signaling by
FHL1
and RIP140, and might provide a new regulation mechanism by which estrogen signaling-related diseases such as breast cancer develop.
...
PMID:Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling. 1940 Nov 55